Weight loss: What to do if GLP-1s like Wegovy alone aren't working
perigon
Last updated: April 16, 2026
A recent review indicates that combination treatments might be more effective for individuals who do not respond to GLP-1 receptor agonists alone. This highlights a potential advancement in managing conditions where GLP-1s are currently used as a primary treatment. The findings suggest a shift towards personalized or augmented therapeutic strategies.
- The review examined the efficacy of GLP-1 receptor agonists, drugs that have gained significant traction in recent years. These medications are widely used for various conditions, including type 2 diabetes and obesity, due to their impact on appetite and glucose regulation. However, a notable portion of patients do not achieve the desired therapeutic outcomes with GLP-1 monotherapy. This necessitates exploring alternative or complementary treatment approaches. The research points towards combining GLP-1 agonists with other medications as a promising strategy to enhance patient response. This could involve agents that target different metabolic pathways or offer synergistic effects, thereby improving glycemic control and promoting weight loss more effectively in non-responders. The implications are significant for clinical practice, potentially leading to more tailored and effective treatment regimens for a broader patient population.
